Caris AI Predicts Brain Metastases in Cancer Patients

Caris Life Sciences has launched two AI-powered signatures designed to predict the risk of brain metastases in patients with breast and lung cancer ^[1][3]. These tools analyze whole exome and whole transcriptome sequencing data to provide early risk assessments ^[1][2]. The announcement marks a significant advancement in precision oncology for high-risk patients ^[3]. The technology identifies specific molecular markers associated with the spread of cancer to the brain ^[2]. These insights are now integrated directly into the Caris Molecular Tumor Board reports ^[3]. Clinicians can use these detailed reports to personalize treatment plans and monitor patients more effectively ^[1]. Brain metastases often result in poor clinical outcomes, making early identification a critical medical priority ^[1][2]. By using AI to scan genomic profiles, the company aims to improve survival rates through proactive clinical intervention ^[3]. These tools represent the latest expansion of the Caris diagnostic suite ^[2].